Ph2 INBRX-109 (Unresectable or Metastatic Conventional Chondrosarcoma)

Ph2 INBRX-109 (Unresectable or Metastatic Conventional Chondrosarcoma)

Es posible que algunos contenidos no estén disponibles en español.

Purpose of this Study

We are doing this study to find out if an experimental drug called INBRX-109 (the study drug) is a safe and effective option for people with unresectable or metastatic conventional chondrosarcoma.

Who Can Participate?

Eligibility

Adults ages 18+ who are diagnosed with unresectable or metastatic conventional chondrosarcoma. For more information on who can participate in this study, please contact the study team at stephanie.weaver@duke.edu.

What is Involved?

Description

If you choose to join this study, during the screening period you will:
  • Have a tumor biopsy (unless a previous tumor tissue sample is available)
  • Have blood draws
  • Have imaging scans (CT or MRI)
  • Have an electrocardiogram (ECG) to check your heart function
If you are eligible for the study drug period, you will:
  • Get a random assignment to receive either the study drug or placebo (inactive substance) by intravenous (IV) infusion
  • Take a dose of 600-1200 mg of N-acetylcysteine and get a prescription for 8 mg dexamethasone
  • Have clinical visits for full physical examination and procedures including urine and blood sample collection
  • Have imaging scans (CT and MRI)
  • Have phone calls with the study team

    • Study Details

    Full Title

    A Randomized, Blinded, Placebo-controlled, Phase 2 Study of INBRX-109 in Unresectable or Metastatic Conventional Chondrosarcoma

    Principal Investigator

    Juneko
    Grilley Olson

    Protocol Number

    PRO00108836

    NCT ID

    NCT04950075

    Phase

    II

    Enrollment Status

    Open to Enrollment
    ClinicalTrials.gov